The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | How can autoSCT outcomes be improved in Hodgkin lymphoma?
Sanjal Desai, MBBS, Mayo Clinic, Rochester, MN, briefly comments on potential strategies for improving outcomes in patients with Hodgkin lymphoma (HL) receiving autologous stem cell transplant (autoSCT). These include adding agents such as PD-1 inhibitors into salvage regimens and incorporating maintenance regimens following transplant. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
Some of the efforts have already been made. So as I said, in relapsed or refractory classic Hodgkin lymphoma, incorporation of PD-1 blockers in salvage regimens. So brentuximab vedotin in combination with nivolumab or nivolumab with ICE chemotherapy or pembrolizumab with GVD chemotherapy. These regimens have led to a higher rate of complete remissions before autologous stem cell transplant and that has in turn… these regimens also have shown higher progression-free survival and we have shown that or we have observed that in a couple of multicenter studies as well real-world studies where incorporation of PD-1 blockers prior to transplant leads to improved post-transplant outcomes compared to chemotherapy or any regimen without PD-1 blockers...
Some of the efforts have already been made. So as I said, in relapsed or refractory classic Hodgkin lymphoma, incorporation of PD-1 blockers in salvage regimens. So brentuximab vedotin in combination with nivolumab or nivolumab with ICE chemotherapy or pembrolizumab with GVD chemotherapy. These regimens have led to a higher rate of complete remissions before autologous stem cell transplant and that has in turn… these regimens also have shown higher progression-free survival and we have shown that or we have observed that in a couple of multicenter studies as well real-world studies where incorporation of PD-1 blockers prior to transplant leads to improved post-transplant outcomes compared to chemotherapy or any regimen without PD-1 blockers. So incorporating better salvage regimens is something that can improve outcomes post-transplant and that is something that’s being already done.
Incorporation of maintenance regimens is another strategy that can improve autologous stem cell transplant outcomes. So we have brentuximab vedotin maintenance as a pretty much standard of care right now in relapsed/refractory classic Hodgkin lymphoma. We have some great data for pembrolizumab maintenance as well.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Onclive: Honoraria; CurioScience: Honoraria; Merck: Research Funding; Beigene: Research Funding.
